Induction of active tolerance after islet transplantation in longstanding diabetic NOD mice by L. lactis-based vaccine combined with low-dose anti-CD3

This abstract has open access
Abstract Summary

The long-term success of islet transplantation as a diabetes treatment depends on halting underlying recurrence of autoimmunity driven by pre-primed autoreactive effector T cells. Low-dose anti-CD3 monoclonal antibodies combined with live Lactococcus lactis secreting proinsulin and IL-10 (LL-PINS+IL-10) restore peripheral tolerance in new-onset diabetic non-obese diabetic (NOD) mice. Therapeutic success depends on residual ?-cell mass at time of intervention, but ?-cell mass rapidly declines at disease onset.  Thus, islet implantation may be used to both enlarge ?-cell mass during treatment, improving likelihood for success in early stage disease, and completely replace ?-cells in more advance disease. In NOD mice with existing autoimmunity and hyperglycemia, kidney capsular islet implantation was performed simultaneously with anti-CD3 treatment alone (monotherapy) or combined with LL-PINS+IL-10 (combination).  Islet-transplantation successfully maintained normoglycemia in 45% of combination treated mice, 28% in those under monotherapy (**p<0,01), and 5% in untreated controls (****p<0,0001 for both therapies). Disease duration prior to intervention in islet recipient mice also affected therapeutic success. Successful mono- and combination therapy protected ?-cell function of islet grafts and preserved remaining endogenous islets. Islet grafts from untreated mice and those where therapy failed were almost completely destroyed and showed striking lymphocytic infiltration. Remarkably, mononuclear infiltration of CD4+ and CD8+ T cells was also present in grafts from cured mice and to the same extent in both treatment groups. CD4+Foxp3+ regulatory T cells (Tregs) were increased in grafts from mice treated with either therapy compared to untreated controls and higher in combination cured vs monotherapy cured mice (**p<0,01).  Pathogenic CD8+IGRP+ effector T cells were blocked from early entry into the islet graft, a phenomenon persisting at least until 6 weeks post-transplantation in therapy-responsive mice. LL-based combination therapy induces peripheral tolerance in longstanding diabetic mice by inducing of Tregs and prevents graft infiltration by autoreactive CD8+ T cells.

Submission ID :
IDS94201
Submission Type
Abstract Topics
Laboratory of Experimental Medicine, University of Leuven, Belgium
Diabetes Unit, Dept. of Medicine, Surgery and Neuroscience, University of Siena; Umberto Di Mario Foundation ONLUS, Toscana Life Sciences, Siena, Italy
ActoBio Therapeutics Inc.
ActoBio Therapeutics, Zwijnaarde, Ghent, Belgium
Clinical and Experimental Endocrinology, KULeuven, Belgium
Diabetes Unit, Department of Medicine, Surgery and Neuroscience, University of Siena and Fondazione Umberto Di Mario ONLUS c/o Toscana Life Science, Siena, Italy
Diabetes Unit Department of Medical Science, Surgery and Neuroscience, University of Siena, Italy; Umberto Di Mario Foundation ONLUS, Toscana Life Sciences, Siena
Diabetes Unit, Department of Medicine, Surgery and Neuroscience, University of Siena and Fondazione Umberto Di Mario ONLUS c/o Toscana Life Science, Siena, Italy
Clinical and Experimental Endocrinology, KULeuven, Belgium
Laboratory of Experimental Medicine, University of Leuven, Belgium

Abstracts With Same Type

Submission ID
Submission Title
Submission Topic
Submission Type
Primary Author
3 visits

KEY DATES

Event dates:
Thursday 25 October - Monday 29 October 2018

Abstract submission deadline:
Monday 14 May 2018

Abstract notification:
July 2018

Early registration deadline:
Monday 3 September 2018

Registration deadline:
Monday 15 October 2018

Contact
British Society for Immunology
+44 (0)20 3019 5901
congress@immunology.org